Pharmaceuticals

Global Injectable Targeted Therapy Market Trends and Growth Analysis 2025–2029

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Injectable Targeted Therapy Market Expected To Expand Between 2025 And 2029?

The injectable targeted therapy market size has seen rapid growth in recent years. It is expected to expand from $57.97 billion in 2024 to $64.22 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.8%. The increase observed in the past period can be attributed to an expanding number of clinical trials for injectable targeted therapies, a heightened focus on precision oncology and immunotherapy, more favorable reimbursement policies for biologic therapies, a rising patient preference for minimally invasive treatment options, and an increase in regulatory approvals for new injectable targeted therapies.

The injectable targeted therapy market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $95.46 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.4%. Factors driving this expansion during the forecast period include the escalating prevalence of chronic and rare illnesses, an increasing demand for tailored medical treatments, the rising preference for biologics over traditional therapies, enhanced understanding of targeted therapies among medical practitioners, and heightened financial commitments to biotechnology and pharmaceutical research and development. Key trends anticipated within this period encompass technological advancements in monoclonal antibodies, the incorporation of digital health platforms for monitoring patients, progress in antibody-drug conjugates, the evolution of bispecific antibodies for cancer treatment, and further innovations in individualized medicine strategies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28250&type=smp

Which Major Market Drivers Are Shaping The Future Of The Injectable Targeted Therapy Market?

The expanding need for personalized medicine is anticipated to fuel the future expansion of the injectable targeted therapy market. Personalized medicine defines a healthcare strategy where prevention, diagnosis, and treatment are customized based on an individual’s genetic makeup, environmental influences, and lifestyle choices. The rise of personalized medicine is propelled by genomic breakthroughs, which facilitate a more profound comprehension of distinct genetic variations, thereby enabling highly precise and targeted therapies that enhance patient results and minimize experimental approaches in treatments. Injectable targeted therapy facilitates personalized medicine through the administration of drugs designed to specifically address a patient’s particular molecular or genetic disease profile, boosting effectiveness and reducing adverse reactions. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA sanctioned 16 novel personalized treatments for rare disease patients, an increase from six in 2022. Among these newly authorized personalized treatments for 2023 were also seven cancer drugs and three designated for other diseases and conditions. Consequently, the expanding demand for personalized medicine is stimulating the advancement of the injectable targeted therapy market.

What Are The Leading Segments Analyzed In The Injectable Targeted Therapy Market?

The injectable targeted therapy market covered in this report is segmented as

1) By Type: Monoclonal Antibodies, Small-Molecules, Immunotoxins, Other Types

2) By Mechanism Of Action: Targeted Inhibition of Signal Transduction Pathways, Targeted Delivery Of Cytotoxic Agents, Immunomodulation

3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular

4) By Application: Oncology, Cardiometabolism, Immunology, Infectious Diseases, Neuroscience, Ophthalmology, Other Applications

5) By End User: Hospitals, Specialty Clinics, Research Laboratories

Subsegments:

1) By Monoclonal Antibodies: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies

2) By Small-Molecules: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mtor Inhibitors

3) By Immunotoxins: Recombinant Immunotoxins, Chemical Conjugates, Fusion Proteins

4) By Other Types: Antibody-Drug Conjugates, Bispecific Antibodies, Peptide-Based Therapeutics

What Are The Major Trends Driving The Growth Of The Injectable Targeted Therapy Market?

Leading corporations within the injectable targeted therapy market are concentrating on developing innovative approaches, such as subcutaneous injections, to enhance the efficiency of drug delivery, improve patient adherence, and more effectively target specific disease pathways. Subcutaneous injection refers to a method of administering medication directly under the skin into the fatty tissue beneath the dermis, facilitating the slow absorption of the drug into the bloodstream. For example, in August 2025, Eisai Co., Ltd., a Japan-based pharmaceutical company, collaborated with Biogen Inc., a US-based biotechnology company, and obtained FDA approval for LEQEMBI IQLIK, a treatment for early Alzheimer’s disease. This is a convenient, once-weekly subcutaneous injection designed for the maintenance treatment of early Alzheimer’s, empowering patients to self-administer at home following initial intravenous therapy. It works by slowing cognitive decline through targeting and clearing amyloid beta plaques and protofibrils, which are critical elements driving Alzheimer’s progression. This formulation not only reduces treatment time but also lowers systemic side effects compared to IV infusions, and minimizes the need for infusion center visits, thereby offering increased independence for both patients and their care partners.

Which Major Industry Participants Are Leading The Injectable Targeted Therapy Market Growth?

Major companies operating in the injectable targeted therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Beigene Ltd., Agenus Inc., and Xilio Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/injectable-targeted-therapy-global-market-report

Which Geographies Are Emerging As Strong Markets For The Injectable Targeted Therapy Industry?

North America was the largest region in the injectable targeted therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in injectable targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Injectable Targeted Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28250&type=smp

Browse Through More Reports Similar to the Global Injectable Targeted Therapy Market 2025, By The Business Research Company

Type 2 Diabetes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Non Insulin Therapies For Diabetes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Diabetic Gastroparesis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diabetic-gastroparesis-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795